<?xml version='1.0' encoding='utf-8'?>
<document id="29050316"><sentence text="Pharmacokinetics and drug-drug interaction between enalapril, enalaprilat and felodipine extended release (ER) in healthy subjects."><entity charOffset="51-60" id="DDI-PubMed.29050316.s1.e0" text="enalapril" /><entity charOffset="62-73" id="DDI-PubMed.29050316.s1.e1" text="enalaprilat" /><entity charOffset="78-88" id="DDI-PubMed.29050316.s1.e2" text="felodipine" /><pair ddi="false" e1="DDI-PubMed.29050316.s1.e0" e2="DDI-PubMed.29050316.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29050316.s1.e0" e2="DDI-PubMed.29050316.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29050316.s1.e0" e2="DDI-PubMed.29050316.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29050316.s1.e1" e2="DDI-PubMed.29050316.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29050316.s1.e1" e2="DDI-PubMed.29050316.s1.e2" /></sentence><sentence text="Since angiotensin-converting enzyme (ACE) inhibitors and calcium antagonists have complimentary mechanisms of action, enalapril, an ACE inhibitor, is used in combination with felodipine, a vascular selective dihydropyridine calcium antagonist, for the treatment of hypertension"><entity charOffset="6-17" id="DDI-PubMed.29050316.s2.e0" text="angiotensin" /><entity charOffset="57-64" id="DDI-PubMed.29050316.s2.e1" text="calcium" /><entity charOffset="118-127" id="DDI-PubMed.29050316.s2.e2" text="enalapril" /><entity charOffset="175-185" id="DDI-PubMed.29050316.s2.e3" text="felodipine" /><entity charOffset="208-231" id="DDI-PubMed.29050316.s2.e4" text="dihydropyridine calcium" /><pair ddi="false" e1="DDI-PubMed.29050316.s2.e0" e2="DDI-PubMed.29050316.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29050316.s2.e0" e2="DDI-PubMed.29050316.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29050316.s2.e0" e2="DDI-PubMed.29050316.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29050316.s2.e0" e2="DDI-PubMed.29050316.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29050316.s2.e0" e2="DDI-PubMed.29050316.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29050316.s2.e1" e2="DDI-PubMed.29050316.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29050316.s2.e1" e2="DDI-PubMed.29050316.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29050316.s2.e1" e2="DDI-PubMed.29050316.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29050316.s2.e1" e2="DDI-PubMed.29050316.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29050316.s2.e2" e2="DDI-PubMed.29050316.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29050316.s2.e2" e2="DDI-PubMed.29050316.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29050316.s2.e2" e2="DDI-PubMed.29050316.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29050316.s2.e3" e2="DDI-PubMed.29050316.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29050316.s2.e3" e2="DDI-PubMed.29050316.s2.e4" /></sentence><sentence text=" The present study was designed to investigate the possible drug-drug interaction between these two agents in Chinese healthy subjects" /><sentence text=" A randomized, open-label, multiple-dose, 3-treatment, 3-period, 6-sequence cross-over study enrolling 12 healthy subjects (six male and six female subjects) was performed" /><sentence text=" Plasma pharmacokinetic studies were performed after 5 mg of enalapril and 5 mg of felodipine were administered alone or concomitantly twice per day for six days, and once in the morning of day seven"><entity charOffset="61-70" id="DDI-PubMed.29050316.s5.e0" text="enalapril" /><entity charOffset="83-93" id="DDI-PubMed.29050316.s5.e1" text="felodipine" /><pair ddi="false" e1="DDI-PubMed.29050316.s5.e0" e2="DDI-PubMed.29050316.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29050316.s5.e0" e2="DDI-PubMed.29050316.s5.e1" /></sentence><sentence text=" All 12 healthy subjects (mean [SD] age, 24" /><sentence text="3 [2" /><sentence text="8] years; body weight, 57" /><sentence text="3 [5" /><sentence text="7] kg; height, 163" /><sentence text="2 [5" /><sentence text="2] cm) completed all scheduled pharmacokinetic studies" /><sentence text=" Geometric mean ratios (with 90% CIs) of AUCτ,ss and Cmax,ss for enalapril administered concomitantly with felodipine vs"><entity charOffset="65-74" id="DDI-PubMed.29050316.s13.e0" text="enalapril" /><entity charOffset="107-117" id="DDI-PubMed.29050316.s13.e1" text="felodipine" /><pair ddi="false" e1="DDI-PubMed.29050316.s13.e0" e2="DDI-PubMed.29050316.s13.e0" /><pair ddi="false" e1="DDI-PubMed.29050316.s13.e0" e2="DDI-PubMed.29050316.s13.e1" /></sentence><sentence text=" enalapril administered alone were 1"><entity charOffset="1-10" id="DDI-PubMed.29050316.s14.e0" text="enalapril" /></sentence><sentence text="025 (0" /><sentence text="80-1" /><sentence text="25) and 1" /><sentence text="065 (0" /><sentence text="70-1" /><sentence text="43), respectively" /><sentence text=" Geometric mean ratios (with 90% CIs) of AUCτ,ss and Cmax,ss for felodipine administered concomitantly with enalapril vs"><entity charOffset="65-75" id="DDI-PubMed.29050316.s21.e0" text="felodipine" /><entity charOffset="108-117" id="DDI-PubMed.29050316.s21.e1" text="enalapril" /><pair ddi="false" e1="DDI-PubMed.29050316.s21.e0" e2="DDI-PubMed.29050316.s21.e0" /><pair ddi="false" e1="DDI-PubMed.29050316.s21.e0" e2="DDI-PubMed.29050316.s21.e1" /></sentence><sentence text=" felodipine administered alone were 1"><entity charOffset="1-11" id="DDI-PubMed.29050316.s22.e0" text="felodipine" /></sentence><sentence text="14 (0" /><sentence text="97-1" /><sentence text="31) and 0" /><sentence text="80 (0" /><sentence text="65-0" /><sentence text="95), respectively" /><sentence text=" There were no severe or serious drug-related adverse events observed during the study" /><sentence text=" Our results revealed that the co-administration of enalapril and felodipine affected the pharmacokinetics of felodipine, but not that of enalapril"><entity charOffset="52-61" id="DDI-PubMed.29050316.s30.e0" text="enalapril" /><entity charOffset="66-76" id="DDI-PubMed.29050316.s30.e1" text="felodipine" /><entity charOffset="110-120" id="DDI-PubMed.29050316.s30.e2" text="felodipine" /><entity charOffset="138-147" id="DDI-PubMed.29050316.s30.e3" text="enalapril" /><pair ddi="false" e1="DDI-PubMed.29050316.s30.e0" e2="DDI-PubMed.29050316.s30.e0" /><pair ddi="false" e1="DDI-PubMed.29050316.s30.e0" e2="DDI-PubMed.29050316.s30.e1" /><pair ddi="false" e1="DDI-PubMed.29050316.s30.e0" e2="DDI-PubMed.29050316.s30.e2" /><pair ddi="false" e1="DDI-PubMed.29050316.s30.e0" e2="DDI-PubMed.29050316.s30.e3" /><pair ddi="false" e1="DDI-PubMed.29050316.s30.e1" e2="DDI-PubMed.29050316.s30.e1" /><pair ddi="false" e1="DDI-PubMed.29050316.s30.e1" e2="DDI-PubMed.29050316.s30.e2" /><pair ddi="false" e1="DDI-PubMed.29050316.s30.e1" e2="DDI-PubMed.29050316.s30.e3" /><pair ddi="false" e1="DDI-PubMed.29050316.s30.e2" e2="DDI-PubMed.29050316.s30.e2" /><pair ddi="false" e1="DDI-PubMed.29050316.s30.e2" e2="DDI-PubMed.29050316.s30.e3" /></sentence><sentence text=" Although the difference in PK parameters was statistically significant, its clinical significance may be limited, considering safety profile observed in the present study" /><sentence text="" /></document>